Compare RemeGen Co., Ltd. with Similar Stocks
Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -205.10% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -69.48
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
HKD 17,688 Million ()
NA (Loss Making)
NA
0.00%
-0.06
7.22%
3.97
Revenue and Profits:
Net Sales:
740 Million
(Quarterly Results - Mar 2026)
Net Profit:
370 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.54%
0%
3.54%
6 Months
4.82%
0%
4.82%
1 Year
71.49%
0%
71.49%
2 Years
190.91%
0%
190.91%
3 Years
127.35%
0%
127.35%
4 Years
173.55%
0%
173.55%
5 Years
-16.62%
0%
-16.62%
RemeGen Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
374.66%
EBIT Growth (5y)
-205.10%
EBIT to Interest (avg)
-69.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.11
Sales to Capital Employed (avg)
0.37
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
26.45
EV to EBIT
-71.48
EV to EBITDA
-98.01
EV to Capital Employed
18.90
EV to Sales
28.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.44%
ROE (Latest)
-40.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
740.50
1,679.60
-55.91%
Operating Profit (PBDIT) excl Other Income
-29.20
679.90
-104.29%
Interest
15.10
14.40
4.86%
Exceptional Items
407.60
702.50
-41.98%
Consolidate Net Profit
370.10
1,382.50
-73.23%
Operating Profit Margin (Excl OI)
-39.40%
404.80%
-44.42%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -55.91% vs 147.18% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -73.23% vs 1,351.13% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,515.50
1,854.20
89.60%
Operating Profit (PBDIT) excl Other Income
480.60
-1,451.50
133.11%
Interest
76.10
78.50
-3.06%
Exceptional Items
696.40
1.70
40,864.71%
Consolidate Net Profit
769.60
-1,592.00
148.34%
Operating Profit Margin (Excl OI)
37.90%
-856.40%
89.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 89.60% vs 55.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 148.34% vs 4.66% in Dec 2024
About RemeGen Co., Ltd. 
RemeGen Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






